Small Intestinal Bacterial Overgrowth and Antimicrobials

Dear Colleagues,

In the Special Issue titled “Small Intestinal Bacterial Overgrowth and Antimicrobials”, we aim to present a comprehensive, multidisciplinary overview of Small Intestinal Bacterial Overgrowth (SIBO)—an increasingly recognized and clinically relevant condition. Edited by Prof. Mislav Radić and Dr. Andrej Belančić, this Special Issue will explore both clinical and preclinical insights into the diagnosis, pathophysiology, and management of SIBO, with particular emphasis on the role of antimicrobial therapies.

Given the complex and multifactorial nature of SIBO, we welcome contributions from a wide range of disciplines such as gastroenterology, clinical pharmacology, infectology, immunology, rheumatology, and related fields, provided the focus is clearly on SIBO. We are particularly interested in studies addressing alterations in gut microbiota specific to SIBO and their impact on host health, antimicrobial resistance challenges in SIBO treatment, and novel antimicrobial, probiotic, or prebiotic strategies aimed at managing SIBO. We also encourage submissions exploring immunological dysregulation in the context of SIBO, the gut–liver axis as it relates to SIBO, and the presence or consequences of SIBO in autoimmune or systemic diseases. Contributions involving preclinical models or translational research are welcome, as long as their relevance to SIBO is clearly established.

As SIBO continues to be linked with a growing number of chronic and systemic conditions, its significance in both clinical and research settings is expanding. At the same time, the field faces considerable challenges, including a lack of standardized diagnostic criteria, limited evidence on optimal treatment approaches, and insufficient data on long-term management. This Special Issue aims to bring together focused research and expert perspectives that directly enhance our understanding of SIBO and support improvements in clinical outcomes.

We believe that Antibiotics and Biomedicines offer excellent platforms for fostering this type of focused, multidisciplinary exchange—connecting clinical practice with the latest scientific findings.

If you are interested in contributing to this Special Issue, please feel free to contact the Guest Editors or reach out to the Editorial Board of the journal. We look forward to your submissions and engaging in productive collaboration.

Dr. Mislav Radić
Dr. Andrej Belančić
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• small intestine bacterial overgrowth
• antibiotics
• probiotics
• gut microbiome